All posts by: Michael Zand

About Michael Zand

Gene-Therapy Update: Mixed Results Don’t Dim Hopes – Barron’s

Continue reading

2018-01-08 NEWS

SMA News Today

GeneTherapy Update: Mixed Results Don’t Dim Hopes
Barron’s
Three companies developing replacement genetherapy treatments provided updates last week on clinical trials. Investors were happy with the news at Audentes Therapeutics (ticker: BOLD), and disappointed with what they heard from Avexis (AVXS) and
FDA Lets AveXis Know the Information It Needs to Approve AVXS-101 for SMA Type 1SMA News Today

all 5 news articles »

Continue reading

2018-01-08 NEWS

SMA News Today

GeneTherapy Update: Mixed Results Don’t Dim Hopes
Barron’s
Three companies developing replacement genetherapy treatments provided updates last week on clinical trials. Investors were happy with the news at Audentes Therapeutics (ticker: BOLD), and disappointed with what they heard from Avexis (AVXS) and
FDA Lets AveXis Know the Information It Needs to Approve AVXS-101 for SMA Type 1SMA News Today
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the …GlobeNewswire (press release)

all 5 news articles »

Continue reading

2018-01-08 NEWS

Wall Street Journal

Stem Cells for Knee Problems? US Doctors Investigate
Wall Street Journal
Jason Dragoo’s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries. The interest highlights a growing demand for the use of